Oramed Pharmaceuticals (NASDAQ:ORMP) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Tuesday.
Separately, HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of Oramed Pharmaceuticals in a report on Wednesday, November 22nd.
Oramed Pharmaceuticals (ORMP) opened at $8.06 on Tuesday. Oramed Pharmaceuticals has a 1-year low of $5.82 and a 1-year high of $11.34.
TRADEMARK VIOLATION WARNING: This report was first posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3079050/valuengine-downgrades-oramed-pharmaceuticals-ormp-to-sell.html.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.
Receive News & Ratings for Oramed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.